
Yahoo · 9 de sept de 2026
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING…
Astrazeneca Plc
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Últimos 195 días · 12/11/25 — 09/09/26
-2.99%
Precio
$ 63.425
Var. %
+1,23%
Volumen operado
823
Precio AZN
US$ 159,47
Teórico (precio / ratio)
AZN ÷ 4
US$ 39,87
Sí, existe el CEDEAR de AZN (Astrazeneca Plc) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es AZN.
El ticker del CEDEAR de Astrazeneca Plc en Argentina es AZN. La acción subyacente cotiza en NYSE con el símbolo AZN.
El CEDEAR AZN tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de AZN.
El CEDEAR AZN cotiza hoy a $ 63.425 en pesos argentinos, con una variación diaria de +1,23%.
La acción subyacente AZN (Astrazeneca Plc) cotiza a US$ 159,47 en su mercado de origen (NYSE).

Yahoo · 9 de sept de 2026
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING…

Yahoo · 9 de sept de 2026
Two Phase 3 victories earned priority review, but approval and launch economics remain ahead.

Yahoo · 9 de sept de 2026
The Imdelltra-Imfinzi combination improved survival and response measures in a 563-patient late-stage lung-cancer trial.
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 41,38
vs teórico
+3,79%
Cotización MEP implícita
$ 1.532,75
Cotización
US$ 43,37
vs teórico
+8,79%
Cotización Cable implícita
$ 1.462,42
El precio teórico del CEDEAR AZN se calcula dividiendo el precio de AZN por el ratio (4). Hoy resulta en US$ 39,87.
En BYMA podés operar AZN en pesos, AZND en dólar MEP y AZNC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR AZN en pesos argentinos, con datos de data912.

Yahoo · 9 de sept de 2026
The focus of this latest data presentation was the drug’s efficacy in reducing moderate and severe exacerbations among COPD patients who continued to experience…

Yahoo · 9 de sept de 2026
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate De…

SeekingAlpha · 9 de sept de 2026
Absci is rated SELL, as its valuation is highly concentrated on ABS-201 with limited partner revenue and an early-stage pipeline. Click for more on ABSI.

Yahoo · 9 de sept de 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew Citi's backing after tozorakimab trial results, supporting an upside case of at least $7 billion in peak sales, rough…

Yahoo · 9 de sept de 2026
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) said a late-stage study of Imdelltra combined with Imfinzi produced improved outcomes in patients with ex…
Noticias vía Finnhub